SCHEMBL1468352

SCHEMBL1468352

COCCCn1c(NC(=O)c2ccco2)nc2cc(C(=O)NCc3cccc(OC)c3)ccc21

nearest known ligand 0.83

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 9/20 0.83
▸ MEN1 O00255 5/20 0.55
▸ KMT2A Q03164 5/20 0.55
▸ TSHR P16473 4/20 0.55
▸ HTT P42858 4/20 0.55
▸ LMNA P02545 3/20 0.55
▸ TDP1 Q9NUW8 3/20 0.55
▸ HSD17B10 Q99714 3/20 0.55
▸ KDM4E B2RXH2 4/20 0.53
▸ USP2 O75604 2/20 0.53
▸ MAPT P10636 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ PKM P14618 2/20 0.52
▸ HPGD P15428 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ ITK Q08881 4/20 0.51
▸ TP53 P04637 2/20 0.51
▸ EHMT2 Q96KQ7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1468488 0.91 ADORA2A (1.00) ADORA2AMEN1KMT2AITKTP53
SCHEMBL1470097 0.90 ADORA2A (0.93) ADORA2AMEN1KMT2AITKTP53
SCHEMBL8231257 0.87 ADORA2A (0.89) ADORA2AMEN1KMT2AITKTP53
SCHEMBL1468015 0.87 ADORA2A (1.00) ADORA2AITKTP53EHMT2
SCHEMBL12744869 0.87 ADORA2A (0.86) ADORA2AITKTP53EHMT2
SCHEMBL1468370 0.87 ADORA2A (1.00) ADORA2AITKTP53EHMT2
SCHEMBL1467942 0.86 ADORA2A (1.00) ADORA2AITK
SCHEMBL1468300 0.86 ADORA2A (1.00) ADORA2AMAPTITKTP53EHMT2
SCHEMBL1468397 0.86 ADORA2A (1.00) ADORA2AITK
SCHEMBL8232572 0.73 ADORA2A (0.69) ADORA2AITKEHMT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110071130-A1 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES PHARMACOPEIA, INC. (US) 2011-03-24 — — US disclosed
US-20110071130-A1 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES PHARMACOPEIA, INC. (US) 2011-03-24 — — US disclosed
US-20110071130-A1 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES PHARMACOPEIA, INC. (US) 2011-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071130-A1 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885MEN1 4657/4885KMT2A 1504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback